Somerset Group LLC purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,613 shares of the company’s stock, valued at approximately $219,000.
Other large investors also recently modified their holdings of the company. Clearwater Capital Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $103,000. SRS Capital Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 208.4% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after purchasing an additional 1,340 shares during the last quarter. Taylor Wealth Management Partners bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at $110,000. Creative Financial Designs Inc. ADV grew its holdings in shares of Merck & Co., Inc. by 155.2% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after purchasing an additional 1,114 shares during the last quarter. Finally, Well Done LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $115,000. 72.18% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms recently commented on MRK. Zacks Investment Research raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a report on Wednesday, September 26th. Bank of America increased their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a report on Monday, July 30th. BMO Capital Markets reaffirmed a “buy” rating and set a $70.00 target price on shares of Merck & Co., Inc. in a report on Sunday, July 22nd. Jefferies Financial Group reaffirmed a “hold” rating and set a $59.00 target price on shares of Merck & Co., Inc. in a report on Sunday, July 15th. Finally, Barclays increased their target price on shares of Merck & Co., Inc. from $70.00 to $75.00 and gave the company an “overweight” rating in a report on Friday, September 7th. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $68.55.
Shares of MRK opened at $71.03 on Monday. The firm has a market cap of $191.27 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 2.22 and a beta of 0.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $72.42.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.03. The business had revenue of $10.47 billion during the quarter, compared to analysts’ expectations of $10.28 billion. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.01 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 4.27 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 5th. Shareholders of record on Monday, September 17th were given a dividend of $0.48 per share. The ex-dividend date of this dividend was Friday, September 14th. This represents a $1.92 annualized dividend and a yield of 2.70%. Merck & Co., Inc.’s payout ratio is currently 48.24%.
In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 228,091 shares of the stock in a transaction on Tuesday, July 31st. The shares were sold at an average price of $65.00, for a total transaction of $14,825,915.00. Following the completion of the sale, the chairman now owns 938,788 shares of the company’s stock, valued at approximately $61,021,220. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Adam H. Schechter sold 107,360 shares of the stock in a transaction on Monday, September 17th. The shares were sold at an average price of $70.18, for a total transaction of $7,534,524.80. Following the sale, the executive vice president now directly owns 100,000 shares of the company’s stock, valued at approximately $7,018,000. The disclosure for this sale can be found here. Insiders have sold a total of 929,360 shares of company stock valued at $64,370,599 in the last three months. 0.32% of the stock is currently owned by corporate insiders.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Recommended Story: Dividend
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.